Why Alvotech’s latest quarter is drawing attention

Alvotech (NasdaqGM:ALVO) is back in focus after Q1 2026 results showed revenue and earnings shortfalls tied to production interruptions during facility upgrades, even as management reaffirmed full year guidance and outlined new biosimilar and manufacturing plans.

The weak Q1 2026 revenue and earnings, together with facility interruptions and a leadership change in the legal team, have coincided with a 90 day share price return of 37.5% decline and a 1 year total shareholder return of 65.88% loss. This points to fading momentum and rising concern over execution risk around Alvotech’s biosimilar roll out and capacity plans.

If Q1 surprised you, now is a good time to see what else is moving in healthcare, including biosimilar peers and other niches, via our 35 healthcare AI stocks

With the stock down sharply over 1 year, trading at a large discount to analyst targets and some intrinsic value estimates, the key question is whether this represents a reset that offers potential upside, or if the market is signaling expectations of limited future growth.

Most Popular Narrative: 77.1% Undervalued

With Alvotech last closing at $3.20 and the most followed narrative putting fair value at $14.00, the gap between price and expectations is wide and heavily debateable.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off patent, potentially driving a step change in topline revenue once approvals are secured.

Want to understand why this valuation leans so high? The story hinges on ambitious revenue ramp assumptions, margin expansion and a rich future earnings multiple that few biotechs command.

The narrative behind the $14.00 fair value blends several moving parts, including expected biosimilar uptake, margin improvement from vertical integration and the chosen 9.13% discount rate that translates future forecasts into today’s dollars.

Result: Fair Value of $14.00 (UNDERVALUED)

However, this hinges on regulatory milestones landing roughly as expected and partner performance holding up, with delays or contract issues capable of quickly shaking that $14.00 narrative.

Next Steps

This story contains elements of both concern and potential, so consider reviewing the numbers and context yourself and weighing up the 3 key rewards and 2 important warning signs in a timely manner.

Ready for more investment ideas?

If this story has you rethinking your watchlist, do not stop here, wider opportunities across sectors may suit your risk profile and income goals.

• Scan for potential bargains by reviewing companies highlighted in our 51 high quality undervalued stocks that combine attractive prices with solid fundamentals.
• Strengthen your defensive core by checking stocks in the solid balance sheet and fundamentals stocks screener (44 results) that prioritise financial resilience and funding flexibility.
• Get ahead of the crowd by reviewing the screener containing 23 high quality undiscovered gems before these under-the-radar ideas gain wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.